Value Evidence and Outcomes, GSK, GSK House, Brentford, Middlesex, UK.
ICON, ICON Clinical Outcome Assessments, Abingdon, UK.
Adv Ther. 2018 Sep;35(9):1378-1399. doi: 10.1007/s12325-018-0760-7. Epub 2018 Aug 13.
This study evaluated patients' experiences with fluticasone furoate/vilanterol (FF/VI) combination therapy in UK patients with asthma or chronic obstructive pulmonary disease (COPD).
Participants aged ≥ 18 years, with self-reported, physician-diagnosed asthma or COPD (≥ 1 year) who had been receiving FF/VI (≥ 3 months) were recruited from UK primary care. This two-phase, mixed-methods study consisted of a semi-structured, telephone-interview phase (qualitative) and a self-completed online/paper-survey phase (quantitative).
The telephone-interview phase included 50 individuals [asthma, n = 25; COPD, n = 25; mean age (SD) 56.7 years (13.3); 50% female]. Of these, 21 with asthma reported that their condition was stable/well controlled and 13 with COPD felt their condition was manageable. Most participants found FF/VI easy to use (asthma, 25; COPD, 23), easy to integrate into their daily routine (asthma, 25; COPD, 24), and able to control symptoms for ≥ 24 h (asthma, 14; COPD, 16). During the survey phase, 199 individuals were recruited [asthma, n = 100; COPD, n = 99; mean age (SD) 63.6 years (15.1); 59.3% female]. Most participants were satisfied/very satisfied with the efficacy of FF/VI in terms of all-day symptom relief (asthma, 84%; COPD, 75%) and found FF/VI easy/very easy to fit into their daily routine (asthma, 99%; COPD, 96%), easy/very easy to use (asthma, 97%; COPD, 92%), and convenient/very convenient to take as instructed (asthma, 95%; COPD, 93%). Significantly more individuals with asthma (87% versus 46%, P < 0.001) and numerically more individuals with COPD (84% versus 76%, P = 0.055) were satisfied/very satisfied with FF/VI compared with their most recent previous maintenance medication.
The majority of individuals in this study had confidence in FF/VI and were satisfied or very satisfied with various key attributes of the treatment.
GSK study HO-15-15503/204888.
GSK.
本研究评估了英国哮喘或慢性阻塞性肺疾病（COPD）患者使用氟替卡松糠酸酯/维兰特罗（FF/VI）联合治疗的患者体验。
参与者年龄≥18 岁，自我报告有经医生诊断的哮喘或 COPD（≥1 年），并接受 FF/VI（≥3 个月）治疗，他们来自英国初级保健机构。这项两阶段、混合方法研究包括半结构式电话访谈阶段（定性）和自我完成的在线/纸质调查阶段（定量）。
电话访谈阶段包括 50 名参与者[哮喘，n=25；COPD，n=25；平均年龄（标准差）56.7（13.3）岁；50%为女性]。其中，21 名哮喘患者报告他们的病情稳定/得到很好的控制，13 名 COPD 患者认为他们的病情可以控制。大多数参与者认为 FF/VI 易于使用（哮喘，25 名；COPD，23 名），易于融入他们的日常生活（哮喘，25 名；COPD，24 名），并能控制症状持续至少 24 小时（哮喘，14 名；COPD，16 名）。在调查阶段，招募了 199 名参与者[哮喘，n=100；COPD，n=99；平均年龄（标准差）63.6（15.1）岁；59.3%为女性]。大多数参与者对 FF/VI 的全天缓解症状的疗效表示满意/非常满意（哮喘，84%；COPD，75%），并认为 FF/VI 易于/非常易于融入他们的日常生活（哮喘，99%；COPD，96%），易于/非常易于使用（哮喘，97%；COPD，92%），并且按照指示服用非常方便/方便（哮喘，95%；COPD，93%）。与最近使用的维持药物相比，哮喘患者（87%比 46%，P<0.001）和 COPD 患者（84%比 76%，P=0.055）中更有明显比例的患者对 FF/VI 表示满意/非常满意。
这项研究中的大多数参与者对 FF/VI 有信心，并对治疗的各种关键属性表示满意或非常满意。
GSK 研究 HO-15-15503/204888。
GSK。
